J. Mark Braughler
Plus aucun poste en cours
Profil
J.
Mark Braughler worked as a Director at Kylin Therapeutics, Inc. and as a Vice President-Translational Medicine at Precigen, Inc. He received his undergraduate degree from the University of Pittsburgh in 1976.
Anciens postes connus de J. Mark Braughler
| Sociétés | Poste | Fin |
|---|---|---|
Kylin Therapeutics, Inc.
 Kylin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kylin Therapeutics, Inc., a cutting-edge biotechnology company, employs a revolutionary RNA nanoparticle technology platform called 'pRNA' to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. This visionary platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies. The formation of Kylin Therapeutics Inc., is a result of a joint partnership between IN-vivo Ventures, LLC, and Golden Pine Ventures, LLC. Together, these two companies can leverage their alliance partners and strong Board of Directors to ensure Kylin's success. A lean, cross-functional management team is set to effect early stage success. This team provides the essential ingredients to develop and promote Kylin to the next level. It is the goal of this team to provide early stage validation and market traction to attract world-class operational management with relevant credentials, track records, and operational experience. | Directeur/Membre du Conseil | 01/07/2013 |
| PRECIGEN, INC. | Corporate Officer/Principal | - |
Formation de J. Mark Braughler
| University of Pittsburgh | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PRECIGEN, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Kylin Therapeutics, Inc.
Kylin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kylin Therapeutics, Inc., a cutting-edge biotechnology company, employs a revolutionary RNA nanoparticle technology platform called 'pRNA' to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. This visionary platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies. The formation of Kylin Therapeutics Inc., is a result of a joint partnership between IN-vivo Ventures, LLC, and Golden Pine Ventures, LLC. Together, these two companies can leverage their alliance partners and strong Board of Directors to ensure Kylin's success. A lean, cross-functional management team is set to effect early stage success. This team provides the essential ingredients to develop and promote Kylin to the next level. It is the goal of this team to provide early stage validation and market traction to attract world-class operational management with relevant credentials, track records, and operational experience. | Commercial Services |